ARQT — Patent US12042487 Expiry Related to ZORYVE
Jun 7, 2037, 12:00:00 AM UTC
Summary
The patent US12042487 related to ZORYVE, a PDE-4 inhibitor drug developed by Arcutis Biotherapeutics Inc, expires today. This patent covers a method to improve the pharmacokinetics of a PDE-4 inhibitor formulation, specifically aimed at reducing gastrointestinal side effects and enhancing patient compliance by managing the spike in Cmax through the combination of the inhibitor with phosphate ester surfactants.
Company
ARCUTIS BIOTHERAPEUTICS INC (ARQT)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.arcutis.comSimilar Events
Patent US11707454 Expiration for ZORYVE
The expiration of patent US11707454 for ZORYVE, a topical treatment containing roflumilast, is set for December 3, 2041. This patent covers the use of roflumilast for treating fungal infections and conditions such as seborrheic dermatitis and various types of tinea infections. The expiration may allow for increased competition in the antifungal market, potentially impacting Arcutis Biotherapeutics Inc's market position as alternatives become available.
patentPatent Expiration for ZORYVE (US11129818)
Patent US11129818 for ZORYVE, a topical formulation of roflumilast, will expire on August 25, 2037, potentially impacting the product's exclusivity and market position. The patent covers improved delivery methods and a longer plasma half-life for the therapeutic, which is significant for treatment effectiveness. As patent expiration may lead to generic competition, this could materially affect Arcutis Biotherapeutics Inc.'s revenues from ZORYVE once exclusivity ends.
Patent ExpirationExpiration of Patent US9907788 for ZORYVE
The patent US9907788 for ZORYVE, assigned to Arcutis Biotherapeutics Inc, is set to expire on June 7, 2037. ZORYVE is a topical treatment that leverages a formulation to improve the bioavailability and efficacy of roflumilast, a phosphodiesterase 4 inhibitor used to treat certain dermatological conditions. The patent's expiration could allow for increased market competition and potential generic versions of the drug, impacting Arcutis's financial landscape.
Patent ExpirationPatent USRE44599 Expiry Related to ZYDELIG
Gilead Sciences Inc's patent USRE44599 related to its product ZYDELIG is set to expire on July 21, 2025. The patent covers compounds that inhibit P13Kδ activity, which is associated with treating diseases involving immunity and inflammation. The expiration could potentially allow for the entry of generic competition in the market, affecting Gilead's revenues derived from ZYDELIG, which is significant for its oncology portfolio.
Patent ExpiryPatent Expiry for US8377921 Related to ZYKADIA
Patent US8377921, related to ZYKADIA, a drug used to treat conditions impacted by ALK, FAK, and other key proteins, is set to expire on November 20, 2027. This expiry could significantly affect Novartis AG and Novartis Pharmaceuticals Corp, as it may lead to generic competition that could impact market share and pricing for ZYKADIA. The patent covers novel compounds essential for the drug's mechanism, indicating the potential financial implications for the companies involved.
Patent ExpiryPatent Expiry for ZYDELIG (US9469643)
The patent for ZYDELIG (US9469643), assigned to Gilead Sciences Inc., is set to expire on September 2, 2033, impacting the product's market exclusivity and future competition. ZYDELIG is a targeted therapy used in the treatment of certain blood cancers. The patent covers formulations, methods of preparation, and uses of the drug, making its expiration critical for both Gilead and potential generic competitors that could enter the market, potentially leading to a decrease in revenue for Gilead as generics become available.
Patent ExpiryPatent US7964592 Expiration for ZYKADIA
The expiration of Patent US7964592 for ZYKADIA, a novel pyrimidine derivative used in pharmaceutical compositions, is set for April 29, 2028. This patent is held by Novartis AG and its subsidiary, NOVARTIS PHARMACEUTICALS CORP. The expiry may lead to increased competition and potential revenue impacts for Novartis, as generic alternatives could enter the market, affecting sales of ZYKADIA.
Patent EventPatent US8865730 Expiration for ZYDELIG
Gilead Sciences Inc.'s patent US8865730, pertaining to ZYDELIG, is set to expire on March 5, 2033. The patent covers polymorphs of a specific compound used in ZYDELIG, a drug indicated for the treatment of certain blood cancers. This expiration may affect Gilead's market exclusivity and could lead to increased competition from generic alternatives, impacting future revenues derived from this product.
Patent ExpirationPatent US11492353 Expiration for VEKLURY
The patent US11492353 for VEKLURY, a treatment for Paramyxoviridae virus infections including Human parainfluenza and Respiratory syncytial virus, is set to expire on December 8, 2031. This patent is assigned to Gilead Sciences Inc, and its expiration may affect the competitive landscape for VEKLURY, allowing for the potential entry of generic alternatives in the market.
Patent Expiration